Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics

Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics

Abstract The use of poly(ADP-ribose) polymerase inhibitors (PARPi) revolutionized the treatment of BRCA-mutated cancers. Identifying patients exhibiting homologous recombination deficiency (HRD) has been proved useful to predict PARPi efficacy. However, obtaining HRD status remains an arduous task d...

Full description

Bibliographic Details
Main Authors: Andréa Witz, Julie Dardare, Margaux Betz, Cassandra Michel, Marie Husson, Pauline Gilson, Jean-Louis Merlin, Alexandre Harlé
Format: Article
Language:English
Published: BMC 2025-02-01
Series:Biomarker Research
Subjects:
Homologous recombination deficiency
HRD status
PARP inhibitors
Genomic scars analysis
BRCA mutations testing
Online Access:https://doi.org/10.1186/s40364-025-00740-y

Internet

https://doi.org/10.1186/s40364-025-00740-y

Similar Items